← Human Trials & Peer-Reviewed Studies
Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients
Plain-language guide to PMID 30641691 (2019): randomized controlled trial study of L-Carnitine in 2 patients, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 30641691
- Journal
- Diabetes & metabolic syndrome
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- El-Sheikh HM et al. (3 authors)
- DOI
- 10.1016/j.dsx.2018.08.035
What This Study Did, in Plain Language
What Was Tested
Researchers studied L-Carnitine in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.
Insulin resistance (IR) is predominant in type 2 diabetic patients.
Who Took Part
According to the abstract, 2 patients were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
Fasting blood samples were collected at baseline, 3 and 6 months after treatment for analysis of fasting and postprandial blood glucose [FBG &PPBG], glycated hemoglobin [HbA1c %], fasting insulin, extracellular part of insulin regulated aminopeptidase [IRAPe] as a novel marker, tumor necrosis factor-alpha [TNF-α], visfatin and lipid panel.
Body mass index [BMI] and homeostasis model assessment of insulin resistance [HOMA-IR] were calculated.
How the Study Was Run
In design terms this was a randomized study.
The patients were allocated by chance, so the L-Carnitine group and the comparison group should start out alike.
What Was Measured
The subject headings attached to it are Biomarkers, Blood Glucose, Carnitine, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents and Insulin Resistance.
Author keywords: Glimepiride, HOMA-IR, Insulin regulated aminopeptidase (IRAPe) and l-carnitine.
What This Means in Plain Language
The paper is a randomized study of L-Carnitine in 2 patients in people with insulin resistance, prediabetes & type 2 diabetes.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2019 (Diabetes & metabolic syndrome), a journal based in Netherlands.
More context: the L-Carnitine compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
L-Carnitine: An amino acid derivative that carries fatty acids into mitochondria for energy production.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.